stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.18
0.82
+4.72%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Return on assets
Dyne Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −60.3%, down 12.8 percentage points from fiscal 2025 (−47.5%). Over the past ten years it has ranged from −120.3% (fiscal 2019) to −32.2% (fiscal 2020); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −47.5% | 26.62 |
| FY2024 | −74.1% | 25.96 |
| FY2023 | −100.1% | (54.17) |
| FY2022 | −45.9% | (7.60) |
| FY2021 | −38.3% | (6.18) |
| FY2020 | −32.2% | 88.15 |
| FY2019 | −120.3% | (3.92) |
| FY2018 | −116.4% | — |
Against its own ten years
Low −120.3%
High −32.2%
Ten-year median
−60.8%
Current reading's percentile
63
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)